NOTE: All in-article links open in a new tab.

Rasburicase: Chemotherapy or Therapeutic Infusion?

Published on 

Tuesday, May 14, 2019

 | RAC Information 
 | FAQ 

Q:

In our Cancer Center, we are giving the drug Rasburicase (Elitek) by infusion. Should we charge this as a chemotherapy infusion or as a therapeutic infusion?



A:

Rasburicase is classified as an antihyperuricemic drug, so you should report the infusion as a therapeutic infusion – not as a chemotherapy infusion.

Article Author: Jeffery Gordon, RN, MSN, CCA, COC
Jeffery Gordon, RN, MSN, CCA, COC, is the Manager of Outpatient Medical Review at Medical Management Plus, Inc. Jeff has over thirty-five years of experience in healthcare including Critical Care, Infection Control, Quality Assurance, Medical Necessity, Outpatient Coding, Medicare Claims data analysis and Medical Record review.

This material was compiled to share information.  MMP, Inc. is not offering legal advice. Every reasonable effort has been taken to ensure the information is accurate and useful.